Literature DB >> 12509807

Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent.

Maike Hartlage-Rübsamen1, Ulrike Zeitschel, Jenny Apelt, Ulrich Gärtner, Heike Franke, Tobias Stahl, Albrecht Günther, Reinhard Schliebs, Milena Penkowa, Volker Bigl, Steffen Rossner.   

Abstract

The beta-site APP-cleaving enzyme (BACE1) is a prerequisite for the generation of beta-amyloid peptides, which give rise to cerebrovascular and parenchymal beta-amyloid deposits in the brain of Alzheimer's disease patients. BACE1 is neuronally expressed in the brains of humans and experimental animals such as mice and rats. In addition, we have recently shown that BACE1 protein is expressed by reactive astrocytes in close proximity to beta-amyloid plaques in the brains of aged transgenic Tg2576 mice that overexpress human amyloid precursor protein carrying the double mutation K670N-M671L. To address the question whether astrocytic BACE1 expression is an event specifically triggered by beta-amyloid plaques or whether glial cell activation by other mechanisms also induces BACE1 expression, we used six different experimental strategies to activate brain glial cells acutely or chronically. Brain sections were processed for the expression of BACE1 and glial markers by double immunofluorescence labeling and evaluated by confocal laser scanning microscopy. There was no detectable expression of BACE1 protein by activated microglial cells of the ameboid or ramified phenotype in any of the lesion paradigms studied. In contrast, BACE1 expression by reactive astrocytes was evident in chronic but not in acute models of gliosis. Additionally, we observed BACE1-immunoreactive astrocytes in proximity to beta-amyloid plaques in the brains of aged Tg2576 mice and Alzheimer's disease patients. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509807     DOI: 10.1002/glia.10178

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  50 in total

1.  Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains.

Authors:  A Kodam; M Maulik; K Peake; A Amritraj; K S Vetrivel; G Thinakaran; J E Vance; S Kar
Journal:  Glia       Date:  2010-08-15       Impact factor: 7.452

2.  Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice.

Authors:  Masaru Yamamoto; Tomomi Kiyota; Masahide Horiba; James L Buescher; Shannon M Walsh; Howard E Gendelman; Tsuneya Ikezu
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 3.  The neglected co-star in the dementia drama: the putative roles of astrocytes in the pathogeneses of major neurocognitive disorders.

Authors:  W K Jo; A C K Law; S K Chung
Journal:  Mol Psychiatry       Date:  2014-01-07       Impact factor: 15.992

Review 4.  The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy.

Authors:  Christopher R Sibley; Matthew J A Wood
Journal:  J Mol Med (Berl)       Date:  2011-07-13       Impact factor: 4.599

Review 5.  Don't forget astrocytes when targeting Alzheimer's disease.

Authors:  Jessica S Sadick; Shane A Liddelow
Journal:  Br J Pharmacol       Date:  2019-02-19       Impact factor: 8.739

Review 6.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

Review 7.  Extracellular Vesicle Biology in Alzheimer's Disease and Related Tauopathy.

Authors:  Annina M DeLeo; Tsuneya Ikezu
Journal:  J Neuroimmune Pharmacol       Date:  2017-11-28       Impact factor: 4.147

8.  Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Authors:  Daniel Paris; Nowell J Ganey; Vincent Laporte; Nikunj S Patel; David Beaulieu-Abdelahad; Corbin Bachmeier; Amelia March; Ghania Ait-Ghezala; Michael J Mullan
Journal:  J Neuroinflammation       Date:  2010-03-08       Impact factor: 8.322

9.  Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Takashi Mori; Naoki Koyama; Gary W Arendash; Yuko Horikoshi-Sakuraba; Jun Tan; Terrence Town
Journal:  Glia       Date:  2010-02       Impact factor: 7.452

10.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.